What is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals is a rna interference medicines company serving enterprise, commercial, consumer, healthcare, financial, real estate, or regulated-market customers.
- Category
- RNA interference medicines
- Headquarters
- Cambridge, MA
- Founded
- See official company history
- Employees
- See latest annual report and company filings
- Total funding
- Public company
- Status
- Public company; Nasdaq: ALNY
What is Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals is a rna interference medicines company headquartered in Cambridge, MA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
Alnylam Pharmaceuticals is a rna interference medicines company headquartered in Cambridge, MA. Its public-company profile is most useful for account planning when combined with current filings, investor materials, job posts, product launches, and partner announcements.
For sellers, Alnylam Pharmaceuticals should be mapped as a scaled public-company account. The best timing signals are earnings commentary, capital spending, hiring clusters, product launches, acquisitions, facility investments, and leadership changes.
What does Alnylam Pharmaceuticals offer?
Alnylam Pharmaceuticals's profile centers on RNAi therapeutics, Rare disease medicines, TTR amyloidosis, Commercial medicines.
- RNAi therapeutics· RNA interference medicines
- Rare disease medicines· RNA interference medicines
- TTR amyloidosis· RNA interference medicines
- Commercial medicines· RNA interference medicines
- Clinical pipeline· RNA interference medicines
- Genetic medicines· RNA interference medicines
How does Alnylam Pharmaceuticals make money?
Alnylam Pharmaceuticals makes money through commercial activity tied to rna interference medicines.
Alnylam Pharmaceuticals monetizes through the model common to rna interference medicines: product sales, recurring services, contracts, leases, subscriptions, transaction volume, servicing, investment management, or usage depending on the operating unit.
Sales angles should connect to measurable priorities such as margin, growth, occupancy, compliance, retention, automation, risk reduction, data quality, customer experience, or field productivity.
Who leads Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals's named executives should be verified on the official leadership or investor-relations page before outreach.
- Alnylam Pharmaceuticals executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Alnylam Pharmaceuticals finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, capital allocation, and budget discipline.
- Alnylam Pharmaceuticals operations or technology leadershipOperations, product, technology, security, or commercial leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operating-improvement purchases.
How do you contact Alnylam Pharmaceuticals's leadership?
Alnylam Pharmaceuticals should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.alnylam.com- Alnylam Pharmaceuticals investor relationsInvestor relations / corporate contactcontact via https://www.alnylam.com
- Alnylam Pharmaceuticals sales or partnershipsCommercial contact routecontact via https://www.alnylam.com
- Alnylam Pharmaceuticals media relationsMedia or communications contact routecontact via https://www.alnylam.com
How is Alnylam Pharmaceuticals funded?
Alnylam Pharmaceuticals's current status is Public company; Nasdaq: ALNY.
Alnylam Pharmaceuticals's capital profile is best understood through its current public-company status: Public company; Nasdaq: ALNY. For public companies, financing and budget signals are usually found in annual reports, quarterly results, debt disclosures, buybacks, acquisitions, capital expenditure plans, and management commentary rather than venture funding rounds.
Before outreach, verify the latest status on the company's investor-relations page and current exchange filings.
How did Alnylam Pharmaceuticals get here?
Alnylam Pharmaceuticals's history should be read through founding, scale-up, public-market ownership, and current product or market focus.
- FoundingAlnylam Pharmaceuticals is foundedThe company begins building in rna interference medicines.
- Scale-upCommercial footprint expandsAlnylam Pharmaceuticals broadens its product, customer, distribution, or geographic reach.
- Public marketsPublic company; Nasdaq: ALNYPublic-company ownership shapes reporting, procurement, and operating priorities.
- 2025Scaled operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, public-company status, and source references.
Who are Alnylam Pharmaceuticals's competitors?
Alnylam Pharmaceuticals competes with larger incumbents and focused specialists in rna interference medicines.
Alnylam Pharmaceuticals — frequently asked questions
